Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-06-16

FDA Approved: BYSTOLIC — Supplemental Application (Allergan, Inc.)

View source ↗

Summary

FDA approved a supplemental application for BYSTOLIC (nebivolol hydrochloride) submitted by Allergan, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BYSTOLIC (nebivolol hydrochloride)

Snippet

SUPPL AP for BYSTOLIC (NEBIVOLOL HYDROCHLORIDE)